Apology to Tippy re SP, page-11

64% of successful Phase II products make it past Phase III, and the vast majority of those make it to market***. Not the "small number" you claim.

Now lets look at the volume of sandalwood oil that might be used in the HPV wart market for pediatrics only.


Lets assume :
- half of the 3.3 million pediatrician HPV wart cases are prescribed the treatment.*
- each bottle is 25 ml **
- assume 2 bottles required over a 12 application period *
- 10% sandalwood oil *

this gives : 8250 litres of Sandalwood oil per year. Thats a lot! Perhaps too much? ok lets half the amount by assuming only 25% are prescribed the treatment (or alternatively only 1 bottle is required). That is still 4125 litres/year! That is more than the Galderma, Lush Cosmetics, and Young Living contracts combined. And that is for just one condition. Beyond that, there is still adult HPV warts to consider. And beyond that, there are several other conditions that are currently in stage II trials (molluscum contagiosum, eczema, oral mucositis, psoriasis).

If that is a "sideshow" as you call it, I can hardly wait for the main attraction.


__________________
* see http://www.asx.com.au/asxpdf/20170110/pdf/43f70xmxdz2vnq.pdf
** see http://www.mollenol.com/molluscum-co
*** see https://www.statnews.com/pharmalot/2016/06/13/clinical-trials-drug-development/